



Chemotherapy Foundation
SYMPOSIUM

UPDATE

Innovative Cancer Therapy for Tomorrow®

A Message From the Chair

Adam M. Brufsky, MD, PhD

The **Chemotherapy Foundation Symposium® (CFS®)** is moving into its 36th year. Three-and-a-half decades of, Innovative Cancer Therapy for Tomorrow®, dedicated professionals educating themselves, updating practice, and caring for patients. Thousands of oncologists have gathered; with a countless number of patients who have been impacted.

Throughout that 36-year history, the pace of oncology research has only accelerated. Every week, new data, new agents, and new guidelines challenge us to evaluate and reevaluate our treatment strategies. In this era of personalized medicine, that challenge becomes even more patient specific.

Chemotherapy is no longer the only option for our patients. From lung cancer to melanoma, leukemia to breast cancer, targeted therapies and immunotherapies have fundamentally changed the way we treat cancer. Medical oncology is not alone in its radical shift; radiation and surgical oncology are quickly changing as well.

As we prepare for the 36th meeting, I encourage you to look back on how much your own practice has changed in the past year. What you've learned in that time is indispensable knowledge for oncologists everywhere. Please join us and share the expertise you've gathered. Together we only advance further.

I hope to see you among the dedicated healthcare professionals at **CFS®**, for 3 days of evidence-based, state-of-the-art cancer care. See you in New York!

Sincerely,

Adam M. Brufsky, MD, PhD

Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center Associate
Director, Clinical Investigation
University of Pittsburgh
Pittsburgh, PA



WHAT'S INSIDE

A Message From the Chair	1
A Look Back	2
2017 Highlights	3

JOIN US!

November 7 – 9, 2018

New York Marriott Marquis
New York, NY

Announcing Tiki Barber as
Keynote Speaker

Best known for his time on the field, Tiki Barber, former New York Giants football player and co-host of CBS Sports Radio's "Tiki & Tierney" will be this year's keynote speaker!

At **CFS®**, Tiki will tell his mother's motivational story to raise awareness and help others through the same journey his family endured.



For more information and to register visit
gotoper.com/go/CFS18NEWS2



A Look Back at Last Year's Meeting

Last year at the 35th meeting of **CFS**[®], we covered a wide range of topics, therapeutic strategies, and tumor types. Here we look back on some of the widest reaching lectures which impact oncology practice, regardless of primary tumor type. From the advent of next-generation sequencing, to the proper management of chemotherapy-induced adverse events, **CFS**[®] covered it all!

The Future of Genetic Testing

At last year's meeting Ankur R Parikh, DO, the medical director of precision medicine at CTCA Philadelphia, led the conversation on the role of next-generation sequencing (NGS) in oncology today. Dr. Parikh discussed how NGS and massively parallel sequencing have led to improved patient care through personalized

diagnoses, prognoses, and therapy selection. Since the Human Genome Project was completed in 2003 the cost of genomic sequencing has radically decreased and become much more widely available. Today, genetic testing can be used to identify biomarkers used for therapy selection or detect resistance mutations as they develop, directing the course of subsequent treatments. Parikh remarked that precision medicine and NGS achieved another milestone in 2017 with the biomarker specific approval for MSI-High solid tumors of pembrolizumab: **"Moving forward we're going to see this more. We're going to get treatment options based on actual molecular profiling instead of site of origin."** Overall, **"the future of NGS is very bright,"** remarked Parikh.



Preventing and Managing Chemotherapy-Induced Nausea and Vomiting

Focusing on a topic that affects all tumor types, Lee S Schwartzberg, MD, FACP, medical oncologist and hematologist from West Cancer Center at the University of Tennessee, spoke on the latest advances in the management and prevention of chemotherapy-induced nausea and vomiting (CINV). Starting with a history lesson Dr. Schwartzberg showed us how far we've come: **"If we start back 40 years ago with the development of cisplatin, that was simply a drug that was impossible to give outside of the hospital, 100% of people threw up continuously with it...and we wandered in the desert for a long time."**

That was, Dr. Schwartzberg told, until 1991 with the development of the first 5-HT3 receptor antagonist. With the addition of NK-1 receptor antagonists, the use of corticosteroids, and the use of other agents

CINV is now regularly managed, but still presents with unique challenges. Even with "optimal" supportive care, up to 60% of patients can still experiencing some grade of CINV. Guiding the audience through the latest breakthroughs, Schwartzberg detailed the results of trials involving the use of NEPA, subcutaneous polymer-based granisetron, and the antipsychotic agent olanzapine. While we've come far, we still have areas of continued need, including investigations into novel agents such as cannabinoids and alternative chemotherapy regimens.

Schwartzberg left us with a reminder: **"The goal is prophylaxis in your patients, not to treat them after they have breakthrough CINV. Your time to take care of them is before chemotherapy."**


Reducing the Clinical Impact of Chemotherapy-Induced Neutropenia

Beyond CINV, another area of great concern for oncologists and their patients undergoing treatment with chemotherapy is chemotherapy-induced neutropenia. Cytotoxic chemotherapy regimens induce hematologic toxicities in patients, the most serious of which is neutropenia. Low neutrophil levels impair the host immune response and are associated with increased risk of infection for patients. Neutropenia, and ultimately the development of febrile neutropenia can result in dose reductions and treatment delays for cancer patients, compromising treatment outcomes. At last year's **CFS**[®], Jeffrey Crawford, MD, professor of medicine at Duke University School of Medicine, covered exactly this. Dr. Crawford detailed the toxic realities myelosuppressive chemotherapy has on the body, and reviewed the methods we have to combat the development of neutropenia or febrile neutropenia. Myeloid growth factors and other prophylactic treatments can improve prospects for patients, and

with the continued development of biosimilar agents our preventative armamentarium has grown. Crawford left us with a steadfast reminder: **“neutropenia is the major risk factor for fever and infection, and reduced chemotherapy dose delivery... individual patient risk assessment and preemptive management is critical.”**



Tiki Barber's Family Journey with Breast Cancer



When Tiki was playing for the University of Virginia Cavaliers, his mother was diagnosed with breast cancer. Initially keeping her diagnosis a secret, Tiki's mother fought through several forms of therapy and came out on top. Now she's been cancer free for 22 years! At **CFS**[®] Tiki will tell her motivational story to raise awareness and help others through the same journey his family endured.

“ CFS[®] has been putting on this conference for a long time—36 years! Greatness isn't doing something once, it's doing something over and over and over again. It's being available when people need you. ”

Register now to hear about all these updates and more!
gotoper.com/go/CFS18NEWS2

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource[®], LLC and Pharmacy Times Continuing Education. Physicians' Education Resource[®], LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource[®], LLC is approved by the California Board of Registered Nursing, Provider #16669 for 26.75 Contact Hours.

PTCE Pharmacy Times Continuing Education[™] is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is approved for a maximum of 22.75 contact hours (0.2275 CEUs) under the ACPE universal activity numbers:



November 7, 2018, Conference Day 1 – 0290-9999-18-099-L01-P (7.75 contact hours)

November 8, 2018, Conference Day 2 – 0290-9999-18-100-L01-P (7.0 contact hours)

November 9, 2018, Conference Day 3 – 0290-9999-18-101-L01-P (8.0 contact hours)

The activity is available for continuing education (CE) credit through December 9, 2018.

PER[®] complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., and Taiho Oncology, Inc.



UPDATE

2 Clarke Drive, Suite 110
Cranbury, NJ 08512

Phone: (888) 949-0045
E-mail: info@gotoper.com

“ This is a can't miss conference. I go every year! ”

Register early to guarantee yourself a seat! Hotel room block is going fast!

36th Annual CFS[®]

Innovative Cancer Therapy for Tomorrow[®]

NOVEMBER 7 – 9, 2018

New York Marriott Marquis
New York, NY

Benefits in Attending this year's CFS[®]!

- Incorporate the latest clinical data into your practice
- Challenge the experts with your most difficult cases
- Network with the top minds in oncology
- 100 Experts. 25 Tumor Types. 3 Days. 1 Meeting.

PROGRAM CO-CHAIRS:



Adam M. Brufsky, MD, PhD
University of Pittsburgh
Pittsburgh, PA



Benjamin Levy, MD
Johns Hopkins Sidney Kimmel
Cancer Center
Washington, D.C.



William Oh, MD
Icahn School of Medicine at
Mount Sinai
New York, NY

For more information and to register visit
gotoper.com/go/CFS18NEWS2

